What are the Fleishner guidelines for managing pulmonary (lung) nodules?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fleischner Society Guidelines for Pulmonary Nodules Management

The 2017 Fleischner Society guidelines recommend a structured approach to pulmonary nodule management based on nodule size, characteristics, and patient risk factors, with different follow-up protocols for solid and subsolid nodules. 1

Solid Nodules Management

Small Solid Nodules (<6 mm, <100 mm³)

  • Low-risk patients: No routine follow-up needed
  • High-risk patients: Optional CT at 12 months
  • Special consideration: Certain high-risk patients with suspicious nodule morphology or upper lobe location may warrant 12-month follow-up 1

Intermediate Solid Nodules (6-8 mm, 100-250 mm³)

  • Low-risk patients: CT at 6-12 months, then consider CT at 18-24 months if stable
  • High-risk patients: CT at 3-6 months, then at 18-24 months if stable 1

Large Solid Nodules (>8 mm, >250 mm³)

  • Consider CT at 3 months, PET/CT, or tissue sampling
  • Management should be guided by the most suspicious features 1

Subsolid Nodules Management

Pure Ground Glass Nodules

  • <6 mm: No routine follow-up
  • ≥6 mm: CT at 6-12 months to confirm persistence, then CT every 2 years until 5 years 1

Part-Solid Nodules

  • <6 mm: No routine follow-up (these are difficult to characterize at this size)
  • ≥6 mm: CT at 3-6 months to confirm persistence. If unchanged and solid component remains <6 mm, annual CT for 5 years
  • Persistent part-solid nodules with solid components ≥6 mm should be considered highly suspicious 1

Multiple Nodules

  • <6 mm: CT at 3-6 months. If stable, consider CT at 2 and 4 years
  • ≥6 mm: CT at 3-6 months. Subsequent management based on the most suspicious nodule(s) 1

Risk Factors to Consider

Important risk factors that influence management decisions include:

  • Smoking history
  • Age
  • Family history of lung cancer
  • Previous history of malignancy
  • Exposure to carcinogens
  • Underlying lung disease 1

Technical Considerations

  • All CT scans should be reconstructed with thin sections (≤1.5 mm, typically 1.0 mm) 1
  • Coronal and sagittal reconstructions are strongly recommended 1
  • Measurements should be made with electronic calipers or semi-automated methods 1
  • For nodule size, use the average of long and short axes rounded to the nearest millimeter 1

Important Caveats

  1. Benign-appearing nodules: No follow-up needed if they show diffuse, central, laminated or popcorn calcification, macroscopic fat, or typical perifissural nodules 1, 2

  2. Incomplete thoracic CT scans: For small nodules (<6 mm) found on incomplete scans, no further investigation is typically needed. For intermediate-size (6-8 mm) nodules, follow-up CT of the complete chest is recommended 1

  3. Special populations: These guidelines do not apply to lung cancer screening, patients with immunosuppression, or patients with known primary cancer 1

  4. Measurement accuracy: Consistent measurement technique is crucial - use the same software for volumetric measurements when assessing growth 1, 3

  5. Adherence challenges: Studies show poor adherence to Fleischner guidelines in clinical practice, with a tendency toward over-management of small nodules 4

The 2017 Fleischner Society guidelines represent a significant update from previous versions, with higher size thresholds for follow-up and less intensive follow-up for very small nodules, reflecting the extremely low risk of malignancy in nodules <6 mm, even in high-risk patients 1, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.